Omeprazol Tecnimede (Omeprazole)

Omeprazole, the active ingredient in Omeprazol Tecnimede, is a proton pump inhibitor presented as a 20 mg tablet for oral use. It reduces stomach acid production and is used to treat conditions such as gastro‑oesophageal reflux disease and peptic ulcer disease in adults.

GNH USA supplies Omeprazol Tecnimede as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omeprazole acts on the gastric acid secretion pathway and is indicated for several acid‑related disorders. - Gastro‑oesophageal reflux disease (GERD): provides symptomatic relief and promotes healing of the esophageal lining. - Peptic ulcer disease: supports ulcer healing by maintaining a less acidic gastric environment. - Zollinger‑Ellison syndrome: controls excessive gastric acid production associated with the condition. - Erosive esophagitis: aids in mucosal healing and reduces further injury. - Helicobacter pylori eradication regimens (as adjunct): enhances the effectiveness of antibiotic therapy by suppressing acid secretion.

Adverse reactions to omeprazole are generally mild and dose‑dependent, but serious events can occur.

Common Side Effects: - Headache: mild, transient headache reported in clinical use. - Diarrhea: loose stools, often self‑limiting. - Nausea: occasional feeling of queasiness. - Abdominal pain: mild discomfort in the stomach area. - Flatulence: increased intestinal gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis linked to altered gut flora. - Acute interstitial nephritis: sudden kidney inflammation. - Hypomagnesemia: low serum magnesium with prolonged use. - Stevens‑Johnson syndrome: rare severe skin reaction. - Fracture risk: possible increase in hip, wrist or spine fractures with long‑term therapy. - Hepatic dysfunction: elevated liver enzymes or hepatitis.

Before initiating therapy, consider patient‑specific factors and follow safe handling practices. - Pregnancy category: use only if the potential benefit justifies the risk. - Breastfeeding: monitor infant for possible effects; benefits may outweigh risks. - Elderly patients: start at the lowest effective dose and monitor renal function. - Concomitant CYP‑interacting drugs: assess for possible altered omeprazole levels. - Long‑term use: evaluate need for ongoing therapy to avoid nutrient malabsorption. - Store below 25°C: keep in the original container, protect from moisture and direct sunlight.

Omeprazole may affect the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, increasing cardiovascular risk. - Atazanavir: decreased absorption leading to therapeutic failure. - Warfarin: potential increase in INR, requiring closer monitoring.

Moderate Interactions (Monitor Closely): - Phenytoin: omeprazole can raise phenytoin levels, risking toxicity. - Digoxin: modest increase in serum digoxin concentrations. - Methotrexate: reduced renal clearance may elevate systemic exposure.